Galina Selivanova

9.3k total citations · 3 hit papers
93 papers, 7.3k citations indexed

About

Galina Selivanova is a scholar working on Oncology, Molecular Biology and Biotechnology. According to data from OpenAlex, Galina Selivanova has authored 93 papers receiving a total of 7.3k indexed citations (citations by other indexed papers that have themselves been cited), including 74 papers in Oncology, 68 papers in Molecular Biology and 26 papers in Biotechnology. Recurrent topics in Galina Selivanova's work include Cancer-related Molecular Pathways (67 papers), Cancer Research and Treatments (26 papers) and RNA modifications and cancer (21 papers). Galina Selivanova is often cited by papers focused on Cancer-related Molecular Pathways (67 papers), Cancer Research and Treatments (26 papers) and RNA modifications and cancer (21 papers). Galina Selivanova collaborates with scholars based in Sweden, Russia and United States. Galina Selivanova's co-authors include Klas G. Wiman, Natalia Issaeva, Vladimir J.N. Bykov, Jan Bergman, Martin Enge, László Székely, Monica Hultcrantz, Marina Protopopova, Joanna Zawacka‐Pankau and Przemyslaw Bozko and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Nucleic Acids Research.

In The Last Decade

Galina Selivanova

93 papers receiving 7.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound

2002 840 citations Vladimir J.N. Bykov, Natalia Issaeva et al. profile →
Small molecule RITA binds to p53, blocks p53–HDM-2 interaction and activates p53 function in tumors

2004 603 citations Natalia Issaeva, Martin Enge et al. profile →
Translating p53-based therapies for cancer into the clinic

2024 86 citations Sylvain Peuget, Xiaolei Zhou et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Galina Selivanova Sweden	48	5.2k	4.5k	1.2k	1.1k	552	93	7.3k
Takashi Tokino Japan	10	6.0k 1.1×	5.4k 1.2×	1.3k 1.1×	1.2k 1.0×	467 0.8×	14	8.1k
Naomi Goldfinger Israel	50	4.3k 0.8×	3.2k 0.7×	1.5k 1.2×	840 0.7×	368 0.7×	93	6.2k
France Carrier United States	32	5.3k 1.0×	3.2k 0.7×	1.2k 1.0×	757 0.7×	519 0.9×	66	6.8k
Peter M. Chumakov Russia	38	4.6k 0.9×	3.0k 0.7×	1.3k 1.0×	822 0.7×	591 1.1×	175	6.7k
Jill Bargonetti United States	31	4.2k 0.8×	3.9k 0.9×	1.3k 1.1×	799 0.7×	266 0.5×	73	5.8k
Athena W. Lin United States	15	6.2k 1.2×	2.9k 0.7×	1.2k 1.0×	574 0.5×	1.1k 1.9×	27	9.0k
Lee Ann Remington United States	13	3.5k 0.7×	3.5k 0.8×	981 0.8×	800 0.7×	398 0.7×	15	5.8k
Michael H.G. Kubbutat Germany	31	4.6k 0.9×	3.6k 0.8×	904 0.7×	983 0.9×	291 0.5×	73	6.5k
Christine E. Canman United States	34	6.0k 1.2×	4.1k 0.9×	1.6k 1.3×	535 0.5×	304 0.6×	49	7.2k
J.M. Trent United States	16	7.0k 1.3×	5.5k 1.2×	1.6k 1.3×	1.1k 1.0×	523 0.9×	25	9.6k

Countries citing papers authored by Galina Selivanova

Since Specialization

Citations

This map shows the geographic impact of Galina Selivanova's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Galina Selivanova with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Galina Selivanova more than expected).

Fields of papers citing papers by Galina Selivanova

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Galina Selivanova. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Galina Selivanova. The network helps show where Galina Selivanova may publish in the future.

Co-authorship network of co-authors of Galina Selivanova

This figure shows the co-authorship network connecting the top 25 collaborators of Galina Selivanova. A scholar is included among the top collaborators of Galina Selivanova based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Galina Selivanova. Galina Selivanova is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhou, Xiaolei, Yue Zhan, Mariana M.S. Oliveira, et al.. (2022). Mutant p53 gain of function mediates cancer immune escape that is counteracted by APR-246. British Journal of Cancer. 127(11). 2060–2071. 17 indexed citations

Zhan, Yue, Xiaolei Zhou, Sylvain Peuget, et al.. (2022). Decreased DNA Damage and Improved p53 Specificity of RITA Analogs. Molecular Cancer Therapeutics. 21(10). 1524–1534. 4 indexed citations

Zhou, Xiaolei, Madhurendra Singh, Gema Sanz, et al.. (2021). Pharmacologic Activation of p53 Triggers Viral Mimicry Response Thereby Abolishing Tumor Immune Evasion and Promoting Antitumor Immunity. Cancer Discovery. 11(12). 3090–3105. 113 indexed citations

Zehl, Martin, Madhurendra Singh, Finn L. Aachmann, et al.. (2020). Class IV Lasso Peptides Synergistically Induce Proliferation of Cancer Cells and Sensitize Them to Doxorubicin. iScience. 23(12). 101785–101785. 18 indexed citations

Peuget, Sylvain, Jiawei Zhu, Gema Sanz, et al.. (2020). Thermal Proteome Profiling Identifies Oxidative-Dependent Inhibition of the Transcription of Major Oncogenes as a New Therapeutic Mechanism for Select Anticancer Compounds. Cancer Research. 80(7). 1538–1550. 14 indexed citations

Zhu, Jiawei, Madhurendra Singh, Galina Selivanova, & Sylvain Peuget. (2020). Pifithrin-α alters p53 post-translational modifications pattern and differentially inhibits p53 target genes. Scientific Reports. 10(1). 1049–1049. 53 indexed citations

Booth, Samuel, et al.. (2020). p53 CRISPR Deletion Affects DNA Structure and Nuclear Architecture. Journal of Clinical Medicine. 9(2). 598–598. 5 indexed citations

Zhang, Fan, Vedrana Tabor, Madhurendra Singh, et al.. (2018). MYC and RAS are unable to cooperate in overcoming cellular senescence and apoptosis in normal human fibroblasts. Cell Cycle. 17(24). 2697–2715. 13 indexed citations

Shi, Yao, Fedor Nikulenkov, Joanna Zawacka‐Pankau, et al.. (2014). ROS-dependent activation of JNK converts p53 into an efficient inhibitor of oncogenes leading to robust apoptosis. Cell Death and Differentiation. 21(4). 612–623. 187 indexed citations

10.

Zandi, Roza, Galina Selivanova, Camilla L. Christensen, et al.. (2011). PRIMA-1Met/APR-246 Induces Apoptosis and Tumor Growth Delay in Small Cell Lung Cancer Expressing Mutant p53. Clinical Cancer Research. 17(9). 2830–2841. 112 indexed citations

11.

Kolpakov, Fedor, Vladimir Poroikov, Galina Selivanova, & Alexander Kel. (2011). GeneXplain — Identification of Causal Biomarkers and Drug Targets in Personalized Cancer Pathways. Journal of Biomolecular Techniques JBT. 22. 9 indexed citations

12.

Székely, László, et al.. (2010). Rescue of p53 Function by Small-Molecule RITA in Cervical Carcinoma by Blocking E6-Mediated Degradation. Cancer Research. 70(8). 3372–3381. 67 indexed citations

13.

Rinaldo, Cinzia, Andrea Prodosmo, Francesca Siepi, et al.. (2009). HIPK2 Regulation by MDM2 Determines Tumor Cell Response to the p53-Reactivating Drugs Nutlin-3 and RITA. Cancer Research. 69(15). 6241–6248. 41 indexed citations

14.

Grinkevich, Vera, Fedor Nikulenkov, Yao Shi, et al.. (2009). Ablation of Key Oncogenic Pathways by RITA-Reactivated p53 Is Required for Efficient Apoptosis. Cancer Cell. 15(5). 441–453. 93 indexed citations

15.

Enge, Martin, Wenjie Bao, Elisabeth Hedström, et al.. (2009). MDM2-Dependent Downregulation of p21 and hnRNP K Provides a Switch between Apoptosis and Growth Arrest Induced by Pharmacologically Activated p53. Cancer Cell. 15(3). 171–183. 131 indexed citations

16.

Zawacka‐Pankau, Joanna, et al.. (2006). Protoporphyrin IX Interacts with Wild-type p53 Protein in Vitro and Induces Cell Death of Human Colon Cancer Cells in a p53-dependent and -independent Manner. Journal of Biological Chemistry. 282(4). 2466–2472. 47 indexed citations

17.

Hällgren, Oskar, Lotta Gustafsson, Heikki Irjala, et al.. (2006). HAMLET triggers apoptosis but tumor cell death is independent of caspases, Bcl-2 and p53. APOPTOSIS. 11(2). 221–233. 59 indexed citations

18.

Bykov, Vladimir J.N., Galina Selivanova, & Klas G. Wiman. (2003). Small molecules that reactivate mutant p53. European Journal of Cancer. 39(13). 1828–1834. 95 indexed citations

19.

Asker, Charlotte, Klas G. Wiman, & Galina Selivanova. (1999). p53-Induced Apoptosis as a Safeguard against Cancer. Biochemical and Biophysical Research Communications. 265(1). 1–6. 68 indexed citations

20.

Bakalkin, Georgy, Galina Selivanova, Tatjana Yakovleva, et al.. (1995). p53 binds single-stranded DNA ends through the C-terminal domain and internal DNA segments via the middle domain. Nucleic Acids Research. 23(3). 362–369. 140 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact